Skip to main content
Premium Trial:

Request an Annual Quote

Marina Reacquires Agricultural, Veterinary Rights to RNAi Tech

Premium

Marina Biotech said this week that it has regained the rights to the use of its transkingdom RNAi technology for agriculture and veterinary applications.

Those rights were previously held by Cambridge Biolabs, formerly ViThera, but the company recently shifted to a new business model, according to Marina. Cambridge Biolabs will retain the rights to the technology for limited veterinary uses, with Marina eligible to receive milestones and royalties.

Additional terms of the arrangement were not disclosed.

"With Cambridge Biolabs' success in transitioning to their new business model, it was an opportunity for Marina to capture the broader agriculture and veterinary uses for its strategic efforts,” Marina President and CEO Michael French said in a statement. “We continue to pursue business relationships that leverage our broad nucleic acid drug discovery platform in the agriculture and veterinary sectors to fund the advancement of nucleic acid-based human therapeutics."

The orally delivered tkRNAi technology involves using attenuated Escherichia coli to transcribe therapeutic shRNAs. Marina picked up the technology through its 2010 acquisition of Cequent Pharmaceuticals.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.